TY - JOUR
T1 - A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
AU - Cadrin-Tourigny, Julia
AU - Bosman, Laurens P.
AU - Nozza, Anna
AU - Wang, Weijia
AU - Tadros, Rafik
AU - Bhonsale, Aditya
AU - Bourfiss, Mimount
AU - Fortier, Annik
AU - Lie, Øyvind H.
AU - Saguner, Ardan M.
AU - Svensson, Anneli
AU - Andorin, Antoine
AU - Tichnell, Crystal
AU - Murray, Brittney
AU - Zeppenfeld, Katja
AU - van den Berg, Maarten P.
AU - Asselbergs, Folkert W.
AU - Wilde, Arthur A. M.
AU - Krahn, Andrew D.
AU - Talajic, Mario
AU - Rivard, Lena
AU - Chelko, Stephen
AU - Zimmerman, Stefan L.
AU - Kamel, Ihab R.
AU - Crosson, Jane E.
AU - Judge, Daniel P.
AU - Yap, Sing-Chien
AU - van der Heijden, Jeroen F.
AU - Tandri, Harikrishna
AU - Jongbloed, Jan D. H.
AU - Guertin, Marie-Claude
AU - van Tintelen, J. Peter
AU - Platonov, Pyotr G.
AU - Duru, Firat
AU - Haugaa, Kristina H.
AU - Khairy, Paul
AU - Hauer, Richard N. W.
AU - Calkins, Hugh
AU - te Riele, Anneline S. J. M.
AU - James, Cynthia A.
N1 - Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press on behalf of European Society of Cardiology.
PY - 2022/8/21
Y1 - 2022/8/21
N2 - AIMS: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. METHODS AND RESULTS: Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P < 0.001). CONCLUSION: Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).
AB - AIMS: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. METHODS AND RESULTS: Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P < 0.001). CONCLUSION: Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).
KW - Arrhythmogenic right ventricular cardiomyopathy
KW - Implantable cardioverter-defibrillators
KW - Sudden cardiac death
KW - Ventricular arrhythmias
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068197100&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30915475
U2 - 10.1093/eurheartj/ehz103
DO - 10.1093/eurheartj/ehz103
M3 - Article
C2 - 30915475
SN - 0195-668X
VL - 40
SP - 1850
EP - 1858
JO - European Heart journal
JF - European Heart journal
IS - 23
ER -